Reduced cardiovascular mortality in oral 1α-hydroxy vitamin D3 users in a haemodialysis population; do CRP and MMP markers of inflammation reflect this finding? (multiple letters) [1]

Nephrology Dialysis Transplantation

Volumn 20, Issue 4, 2005, Pages 846-

  Boucher, Barbara J ^a   Shoji, Tesuo ^b  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; C REACTIVE PROTEIN; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; VITAMIN D;

BANGLADESH; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; ENZYME BLOOD LEVEL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; LETTER; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK REDUCTION; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; MATRIX METALLOPROTEINASE 2; RENAL DIALYSIS;

EID: 17144366992     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh678     Document Type: Letter

References (0)